Xvivo Perfusion Valuation

Q: What is the Fair Price of 0RKL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0RKL (SEK312.75) is trading below our estimate of [[fair value]] (SEK434.25)

Is 0RKL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RKL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

SEK 434.25

Fair Value

28.0% undervalued

Number of Analysts

Below Fair Value: 0RKL (SEK312.75) is trading below our estimate of fair value (SEK434.25)

Significantly Below Fair Value: 0RKL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RKL?

Key metric: As 0RKL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RKL. This is calculated by dividing 0RKL's market cap by their current earnings.
What is 0RKL's PE Ratio?
PE Ratio	72.9x
Earnings	SEK 137.00m
Market Cap	SEK 9.99b

0RKL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	11.4x
Enterprise Value/EBITDA	80.7x
PEG Ratio	1.5x

Price to Earnings Ratio vs Peers

How does 0RKL's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RKL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	49.2x
AMS Advanced Medical Solutions Group	59.7x	39.17%	UK£423.2m
TSTL Tristel	30.3x	19.05%	UK£186.1m
CTEC ConvaTec Group	39.6x	16.92%	UK£5.6b
CRW Craneware	67.3x	24.09%	UK£745.9m
0RKL Xvivo Perfusion	72.9x	48.09%	SEK 10.0b

Price-To-Earnings vs Peers: 0RKL is expensive based on its Price-To-Earnings Ratio (72.9x) compared to the peer average (49.2x).

Price to Earnings Ratio vs Industry

How does 0RKL's PE Ratio compare vs other companies in the European Medical Equipment Industry?

4 Companies	Price / Earnings	Estimated Growth	Market Cap

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 0RKL is expensive based on its Price-To-Earnings Ratio (72.9x) compared to the European Medical Equipment industry average (32x).

Price to Earnings Ratio vs Fair Ratio

What is 0RKL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RKL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	72.9x
Fair PE Ratio	80.7x

Price-To-Earnings vs Fair Ratio: 0RKL is good value based on its Price-To-Earnings Ratio (72.9x) compared to the estimated Fair Price-To-Earnings Ratio (80.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RKL forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 312.75	SEK 448.50 +43.41%	14.02%	SEK 520.00	SEK 335.00	n/a	6
May ’26	SEK 313.33	SEK 448.50 +43.14%	14.02%	SEK 520.00	SEK 335.00	n/a	6
Apr ’26	SEK 291.38	SEK 476.17 +63.42%	17.05%	SEK 567.00	SEK 325.00	n/a	6
Mar ’26	SEK 445.00	SEK 518.67 +16.55%	8.84%	SEK 567.00	SEK 460.00	n/a	6
Feb ’26	SEK 464.00	SEK 522.00 +12.50%	8.06%	SEK 567.00	SEK 480.00	n/a	6
Jan ’26	SEK 489.00	SEK 538.17 +10.05%	7.79%	SEK 584.00	SEK 480.00	n/a	6
Dec ’25	SEK 471.13	SEK 538.17 +14.23%	7.79%	SEK 584.00	SEK 480.00	n/a	6
Nov ’25	SEK 450.35	SEK 545.67 +21.17%	6.26%	SEK 584.00	SEK 480.00	n/a	6
Oct ’25	SEK 502.00	SEK 549.00 +9.36%	6.57%	SEK 584.00	SEK 480.00	n/a	6
Sep ’25	SEK 530.65	SEK 549.00 +3.46%	6.57%	SEK 584.00	SEK 480.00	n/a	6
Aug ’25	SEK 515.40	SEK 549.00 +6.52%	6.57%	SEK 584.00	SEK 480.00	n/a	6
Jul ’25	SEK 418.50	SEK 440.00 +5.14%	13.89%	SEK 520.00	SEK 340.00	n/a	6
Jun ’25	SEK 431.00	SEK 408.00 -5.34%	12.02%	SEK 468.00	SEK 340.00	n/a	6
May ’25	SEK 381.50	SEK 408.00 +6.95%	12.02%	SEK 468.00	SEK 340.00	SEK 313.33	6
Apr ’25	SEK 275.00	SEK 382.60 +39.13%	9.01%	SEK 425.00	SEK 340.00	SEK 291.38	5
Mar ’25	SEK 276.31	SEK 382.60 +38.47%	9.01%	SEK 425.00	SEK 340.00	SEK 445.00	5
Feb ’25	SEK 284.52	SEK 389.60 +36.93%	7.81%	SEK 425.00	SEK 340.00	SEK 464.00	5
Jan ’25	SEK 329.52	SEK 377.00 +14.41%	16.34%	SEK 450.00	SEK 280.00	SEK 489.00	5
Dec ’24	SEK 272.76	SEK 363.75 +33.36%	17.10%	SEK 450.00	SEK 280.00	SEK 471.13	4
Nov ’24	SEK 230.73	SEK 371.67 +61.08%	18.84%	SEK 450.00	SEK 280.00	SEK 450.35	3
Oct ’24	SEK 276.44	SEK 391.67 +41.68%	11.53%	SEK 450.00	SEK 340.00	SEK 502.00	3
Sep ’24	SEK 289.50	SEK 391.67 +35.29%	11.53%	SEK 450.00	SEK 340.00	SEK 530.65	3
Aug ’24	SEK 323.00	SEK 376.67 +16.62%	7.22%	SEK 405.00	SEK 340.00	SEK 515.40	3
Jul ’24	SEK 303.55	SEK 376.67 +24.09%	7.22%	SEK 405.00	SEK 340.00	SEK 418.50	3
Jun ’24	SEK 286.57	SEK 376.67 +31.44%	7.22%	SEK 405.00	SEK 340.00	SEK 431.00	3
May ’24	SEK 305.48	SEK 370.00 +21.12%	7.24%	SEK 405.00	SEK 340.00	SEK 381.50	3

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

SEK 442.21

Fair Value

29.3% undervalued

Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/21 23:57
End of Day Share Price	2025/05/21 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Dylan van Haaften	Bryan Garnier & Co
Maria Vara Fernández	Bryan Garnier & Co
Kristofer Liljeberg-Svensson	Carnegie Investment Bank AB